A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Registrational; Therapeutic Use
- Acronyms VERIFY
- Sponsors AstraZeneca; Sanofi Genzyme
- 13 Jul 2017 This trial was completed in Spain , according to European Clinical Trials Database.
- 05 Apr 2017 This trial was completed in Denmark, according to European Clinical Trials Database.
- 28 Jan 2017 This trial was completed in Czech Republic, according to European Clinical Trials Database.